PointCheck

Target SDGs

Target Users (Target Impact Group)

Small and Medium-sized Enterprises, Public Sector Agencies

Distributors / Implementing Organizations

The company is supported by MIT Innovation Initiative, the MIT Deshpande Center for Technological Innovation, the MIT Sandbox Innovation Fund, the Martin Trust Center for Entrepreneurship, the MIT Translational Fellows Program, and the MIT Venture Mentoring Service.

Countries

Spain, United States

Manufacturing/Building Method

Leuko is working on developing prototypes and commercializing the technology with help from the MIT Innovation Initiative, the MIT Deshpande Center for Technological Innovation, the MIT Sandbox Innovation Fund, the Martin Trust Center for Entrepreneurship, the MIT Translational Fellows Program, and the MIT Venture Mentoring Service.

Intellectural Property Type

Patent

User Provision Model

This product is in the prototype phase and is not available for distribution yet.

Distributions to Date Status

None

Design Specifications

The design of the device allows chemotherapy patients to prevent infections from needle-based tests. The device uses imaging technique which is non-invasive and thus quick check on white blood cell count can be done. The device is portable enough to be used in a clinic or home applications where the patient can have access to daily checks on their blood count. The device is enclosed in a plastic casing and is suitable for use in the home, clinic, or healthcare centers.

PointCheck™ is able to determine if white cell levels are dangerously low by imaging the blood flowing through the capillaries in the finger. PointCheck does this without having to extract any blood

Product Schematics

Technical Support

Not yet available as product is in prototype stage

Replacement Components

The replaceable component includes the battery

Lifecycle

2-5 years

Manufacturer Specified Performance Parameters

Accurately measure white blood cell levels.

Vetted Performance Status

The team showed that the device could accurately determine whether white blood cell levels were too low, in a study of 11 patients undergoing chemotherapy.

Safety

No known safety hazards are related to this product.

Complementary Technical Systems

A reliable power source is required for the device to function and read the blood flow.

Academic Research and References

Compliance with regulations

None yet as product is in prototype stage

Evaluation methods

The product was tested for its accuracy in detecting low white blood cell levels.

Other Information

None